Diabetes is a chronic metabolic disorder wherein the body is either unable to produce insulin (glucose digesting hormone) or unable to utilize the produced insulin to metabolize blood glucose. This condition results in increased blood glucose level, which leads to various chronic and life-threatening diseases. Insulin is a hormone secreted by β-cells of pancreas in order to metabolize the blood sugar. The insulin market is a rapidly growing market. Demand for premixed and long-acting insulin derivatives is growing rapidly due to rising incidences of type 1 diabetes. This report focuses on identifying the current scenario as well as the future market potential for insulin globally. Additionally, the insulin market in China is also analyzed and studied thoroughly. The insulin market is segmented based on two important parameters: by mode of action and by source. By mode of action, the market (global and China) is categorized as rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin derivatives. Furthermore, by source, the market is categorized as human insulin and modern insulin.
Get PDF containing the Forthcoming Market Trends of Global and China Insulin at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=259
Long-acting insulin derivatives is projected to be the fastest growing segment, expanding at a CAGR of 8.7% during the forecast period from 2013 to 2019. According to the World Health Organization (WHO), more than 366 million people worldwide were diagnosed with diabetes in 2011 and an additional 280 million are expected to be diagnosed over the next 20 years. Majority of these patients are likely to be from emerging markets such as China and India.
Rising demand for long-acting insulin derivatives is attributed to advantages such as reduced number of doses compared to other derivatives. Moreover, strong pipeline, lack of stringent regulations on price capping and high entry barriers for biosimilar manufacturers are other important growth drivers in the market. The market for modern insulin is also expected to increase during the forecast period from 2013 to 2019 due to various factors such as ease-of-administration and higher efficacy.
In China, premixed insulin derivatives accounted for more than 50% of the market in 2012. Large population of type 1 diabetes patients and rising preference for insulin as diabetes treatment (both type 1 and type 2) are some of the factors contributing to the growth of the insulin market in China. Moreover, improving medical infrastructure, changing lifestyle, increased consumption of fast food and changing dietary habits are some of the factors expected to drive the insulin market in China.
The global insulin market is highly consolidated and dominated by few market players such as Eli Lilly and Company, Sanofi, and Novo Nordisk A/S. Moreover, these players account for more than 80% of the total insulin market in China. Domestic players such as Shanghai Fosun Pharmaceutical Co., Ltd. and Tonghua Dongbao hold a small share in the Chinese market.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453